EVEREST · Extracellular Vesicle Research Exchanges for Advanced Biomarkers and Therapeutics
Horizon Europe — Marie Skłodowska-Curie Actions
- Duration
- 2025-01-01 → 2028-12-31
- EU contribution
- €1,311,000
- Participants
- 22
- Scheme
- HORIZON-TMA-MSCA-SE
Lines connect the coordinator with its partners.
Project objective
The EVEREST project is a pioneering consortium in Extracellular Vesicle (EVs) research, bringing together 22 institutions from 11 countries, including 3 UK partners. This interdisciplinary consortium is distinguished by an ambitious plan for over 285 months of staff exchanges, engaging at least 81 fellows. Research-Innovation programme is structured into four pivotal work packages:1.Combining Expertise and Resources for Advancing Standardised Characterisation and Isolation of EVs: Focused on harmonizing methods for EV isolation across diverse tissues and samples, enhancing the consistency and reliability of EV research.2.Jointly Investigating EVs in Health or Disease, and Enhancing Translational Biomarker Discovery: Concentrated on exploring the roles of EVs in various health conditions and diseases, with a particular emphasis on identifying and validating new biomarkers for diagnostic and prognostic applications.3.Uniting Capacities, Advancing EV-Based Therapeutics or Drug Delivery: Dedicated to developing innovative EV-based treatments and drug delivery mechanisms, targeting key health challenges like cancer and cardiovascular diseases.4.Catalysing commercial development of EV-based technologies: Aiming to bridge the gap between research and practical application, this work package focuses on preparing EV-based solutions for large-scale production and market introduction.At its core, EVEREST is committed to significantly enhancing the capabilities of participating institutions and fostering career advancement for involved fellows. By positioning EVs as critical tools for biomarker discovery and therapeutic applications, the project aims to make substantial contributions to personalized medicine and improved health outcomes, ultimately translating research breakthroughs into clinical practice.
Original text from CORDIS.
Participants
- UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN · DublinCoordinatorIreland
- ACOUSORT AB · LundSweden
- BIOREPERIA AB · LinkopingSweden
- DE ROTOS Y DESCOSIDOS SC · VALLADOLIDSpain
- FOX BIOSYSTEMS NV · DiepenbeekBelgium
- FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD M.P. · SevillaSpain
- JUSTUS-LIEBIG-UNIVERSITAET GIESSEN · GIESSENGermany
- LINKOPINGS UNIVERSITET · LinkopingSweden
- LUXEMBOURG INSTITUTE OF SCIENCE AND TECHNOLOGY · Esch Sur AlzetteLuxembourg
- MURSLA LIMITED · LONDONUnited Kingdom
- PHARMAHUNGARY 2000 KISERLETES ES KLINIKAI KUTATASFEJLESZTESI KORLATOLTFELELOSSEGU TARSASAG · SzegedHungary
- REGION HOVEDSTADEN · HillerodDenmark
- SIRIUSXT LIMITED · DublinIreland
- SOUTH EAST TECHNOLOGICAL UNIVERSITY · WaterfordIreland
- THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN · DublinIreland
- THE QUEEN'S UNIVERSITY OF BELFAST · BELFASTUnited Kingdom
- UNIVERSIDAD DE VIGO · VIGO PONTEVEDRASpain
- UNIVERSIDADE NOVA DE LISBOA · LisboaPortugal
- UNIVERZITA KOMENSKEHO V BRATISLAVE · BRATISLAVA 1Slovakia
- VALSTYBINIS MOKSLINIU TYRIMU INSTITUTAS INOVATYVIOS MEDICINOS CENTRAS · VILNIUSLithuania
- VESICULAB LTD · NOTTINGHAMUnited Kingdom
- XENOPAT SL · HOSPITALET DE LLOBREGATSpain
Links
Data: CORDIS, © European Union